申请人:MERRELL DOW PHARMACEUTICALS INC.
公开号:EP0116373A1
公开(公告)日:1984-08-22
Derivates of 2H-[1]benzoxepino[5,4-b]-1,4-oxazine, such as trans-(4a, 11b)-3,4,4a,5,6,11b-hexahydro-10-methoxy-2H [1]benzoxepino[5,4-b]-1,4-oxazine, are prepared by acylating a trans-4-amino-2,3,4,5-tetrahydro-1-benzoxepin-5-ol, cyclizing the resulting chloroacetamido alcohol, reducing the 1,4-oxazine-3(4H)-one so obtained, acylating the resulting 2H-[1]benzoxepino[5,4-b]-1,4-oxazine, and reducing the N-acyl-2H-[1]benzoxepino[5,4,-b]-1,4-oxazine so obtained. The novel compounds disclosed herein possess useful antihypertensive properties.
2H-[1]benzoxepino[5,4-b]-1,4-oxazine 的衍生物,例如反式-(4a, 11b)-3,4,4a,5,6,11b-hexahydro-10-methoxy-2H [1]benzoxepino[5,4-b]-1,4-oxazine, 是通过酰化反式-4-氨基-2,3,4,5-四氢-1-苯并氧杂卓-5-醇来制备的、环化得到的氯乙酰胺醇,还原得到的 1,4-恶嗪-3(4H)-酮,酰化得到的 2H-[1]苯并氧杂卓[5,4-b]-1,4-恶嗪,还原得到的 N-酰基-2H-[1]苯并氧杂卓[5,4,-b]-1,4-恶嗪。本文公开的新型化合物具有有用的抗高血压特性。